Doença de Chagas aguda: vias de transmissäo aspectos clínicos e resposta a terapêutica específica em casos diagnosticados em um centro urbano

Yasuda, Maria Aparecida Shikanai; Lopes, Marta Heloisa; Tolezano, J. E; Umezawa, Eufrosina Setsu; Amato Neto, Vicente; Barreto, A. C. Pereira; Higaki, Y; Moreira, Antonio Augusto Baillot; Funayama, G; Barone, A. A; Duarte, Alberto José da Silva; Odone. V; Cerri, Giovanni Guido; Sato, M; Possi, D; Shiroma, Mario.
Rev. Inst. Med. Trop. Säo Paulo ; 32(1): 16-27, jan.-fev. 1990. tab
Artigo em Português | LILACS | ID: lil-89018

Documentos relacionados

  1. Benznidazole, itraconazole, and their combination for the treatment of chronic experimental Chagas disease in dogs.
  2. Perspectives for a new drug candidate for Chagas disease therapy.
  3. Reduced Trypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease.
  4. Enzymatic synthesis of amlodipine amides and evaluation of their anti-<i>Trypanosoma cruzi</i> activity.
  5. Benzonidazole treatment has a beneficial effect on cells infected with the Colombian strain of Trypanosoma cruzi.
  6. In vitro evaluation of 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole derivatives against replicative and infective stages of Trypanosoma cruzi.
  7. Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi.
  8. Antiparasitary and antiproliferative activities in vitro of a 1,2,4-oxadiazole derivative on Trypanosoma cruzi.
  9. Population pharmacokinetics and biodistribution of benznidazole in mice.
  10. Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.